What CRISPR Means for Patients Today
For patients with approved indications, CRISPR represents a genuine cure rather than lifelong management. A child with sickle cell disease who receives a successful CRISPR edit may never need a transfusion or pain crisis management again. The economic implications of single-treatment cures versus decades of chronic disease management are profound for healthcare systems worldwide.
Access and cost are immediate challenges. Current CRISPR therapies cost over one million dollars per patient. Manufacturing autologous therapies — those using the patient’s own edited cells — is complex and cannot yet be scaled to global need. Allogeneic approaches using pre-made “off-the-shelf” edited cells may eventually lower costs.
KEY TAKEAWAYS
- First CRISPR therapy for sickle cell disease was FDA-approved in 2023
- Over 50 gene-editing clinical trials are currently active globally
- Off-target editing risks are declining with newer precision tools
- Current cost exceeds $1M per patient; scaling remains a challenge
- Germline editing in heritable embryos remains ethically prohibited
- Delivery technology is the next key frontier for reaching more tissues